Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment

Mary A. De Groote, Payam Nahid, Leah Jarlsberg, John L. Johnson, Marc Weiner, Grace Muzanyi, Nebojsa Janjic, David G. Sterling, Urs A. Ochsner

1 SomaLogic, Inc, Boulder, Colorado, United States of America, 2 Department of Microbiology, Immunology and Pathology, Colorado State University Campus, Fort Collins, Colorado, United States of America, 3 Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, United States of America, 4 Tuberculosis Research Unit, Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, United States of America, 5 Division of Infectious Diseases, University of Texas Health Science Center, San Antonio, Texas, United States of America, 6 Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda

Abstract

In an unbiased approach to biomarker discovery, we applied a highly multiplexed proteomic technology (SOMAscan, SomaLogic, Inc, Boulder, CO) to understand changes in proteins from paired serum samples at enrollment and after 8 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in the Center for Disease Control and Prevention’s Tuberculosis Trials Consortium (TBTC) Study 29. This work represents the first large-scale proteomic analysis employing modified DNA aptamers in a study of active tuberculosis (TB). We identified multiple proteins that exhibit significant expression differences during the intensive phase of TB therapy. There was enrichment for proteins in conserved networks of biological processes and function including antimicrobial defense, tissue healing and remodeling, acute phase response, pattern recognition, protease/anti-proteases, complement and coagulation cascade, apoptosis, immunity and inflammation pathways. Members of cytokine pathways such as interferon-gamma, while present, were not as highly represented as might have been predicted. The top proteins that changed between baseline and 8 weeks of therapy were TSP4, TIMP-2, SEPR, MRC-2, Antithrombin III, SAA, CRP, NPS-PLA2, LEAP-1, and LBP. The novel proteins elucidated in this work may provide new insights for understanding TB disease, its treatment and subsequent healing processes that occur in response to effective therapy.

Citation: De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, et al. (2013) Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment. PLoS ONE 8(4): e61002. doi:10.1371/journal.pone.0061002

Editor: Robert B. Sim, Oxford University, United Kingdom

Received November 26, 2012; Accepted March 5, 2013; Published April 18, 2013

Copyright: © 2013 De Groote et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The entire sample analysis was funded by SomaLogic, Inc. Funding for recruitment, enrollment and clinical and laboratory follow-up of TBTC Study 29 patients was provided by the United States Centers for Disease Control and Prevention. SomaLogic had no role in study design or patient selection, but conducted the assay and data analysis. SomaLogic decided what and when to publish, and prepared the manuscript with input from the co-authors listed.

Competing Interests: NJ, DS and UO are employees and shareholders of SomaLogic, Inc. MAD is a Consultant to SomaLogic, Inc. The entire sample analysis was funded by SomaLogic, Inc. A provisional patent has been filed by SomaLogic. The patent name is “Tuberculosis Biomarkers and Uses Thereof”, and the application number is 61/623,732. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

* E-mail: uochsner@somalogic.com

Introduction

Using an unbiased approach with a highly multiplexed comprehensive platform, our goal in this study was to identify and quantify protein markers that are present in patients diagnosed with culture-confirmed active TB and that change in response to highly efficacious drug therapy.

In our previous work in lung cancer we performed a large scale application of our platform technology to identify markers capable of diagnosing early onset lung cancer [1]. In this study we used the same modified aptamer array to quantitate 1,030 proteins in serum of patients diagnosed with active TB disease and monitor changes in all markers to better understand the evolution of protein markers as the disease improves on anti-mycobacterial therapy. SOMAscan proteomic technology is based on slow off-rate modified aptamers (SOMAmers), with improved binding properties due to long dissociation rates (generally >30 min) and the incorporation of modified nucleotides that lead to higher affinity of these reagents as compared to standard RNA or DNA aptamers. SOMAmers are made from single-stranded DNA (ssDNA) that contain pyrimidine residues modified at their 5′-prime position to introduce functional groups not present in natural nucleic acids, such as mimics of amino acid side-chains. SOMAmers have several advantages over antibodies, including lower molecular weight, higher multiplexing capabilities (low cross-reactivity, universally-applicable assay conditions), chemical stability (to heat, drying, and solvents, reversible renaturation), ease of reagent manufacturing, consistent lot-to-lot performance and lower cost (fully synthetic).

The Version 2 SOMAscan assay generates simultaneous quantitative measurements of 1,030 human proteins in serum, plasma, CSF or tissue lysate [2] in a small (<100 µl) sample volume. Across all 1,030 proteins, the median lower limit of quantitation is 0.3 picomolar (pM), with a dynamic range of >5 logs, and a median coefficient of variation (%CV) of 5% [3].

This proof-of-principle study is the first large-scale unbiased targeted proteomic analysis employing modified DNA aptamers and we sought to identify and quantify protein markers that are...
associated with active TB and that changed in response to four-drug treatment. This pilot study was made possible due to an archived collection of specimens nested into Tuberculosis Trials Consortium (TBTG) Study 29, a phase 2B clinical trial which evaluated rifapentine in place of rifampin in combination with isoniazid, ethambutol and pyrazinamide for the treatment of drug-susceptible TB [4].

Results

Participant Characteristics

Clinical characteristics of the 39 participants included in this study are listed in Table 1. Participants completed between 6 and 24 months of anti-TB treatment. Follow-up through the end of treatment did not reveal any treatment failures. One participant had INH and RIF resistant tuberculosis; one participant had mono-drug resistance to INH and one had dual resistance (to streptomycin and rifampin), all were detected after the participants completed intensive phase treatment. Four participants received between 3–5 days of 4 drug, standard chemotherapy prior to enrollment.

Sample Handling and Analysis

A small systematic difference (4%) in the overall protein concentrations between the baseline and 8 week sample sets was removed during normalization. Three samples had elevated hemoglobin levels and correspondingly low haptoglobin levels (data not shown) when compared both to other subjects and internal assay calibrators suggesting some degree of hemolysis. No other evidence of sample processing errors [3] was observed so all samples were considered fit for inclusion in the subsequent data analysis.

Nonspecific Markers of Active TB

Serum protein concentrations in TB patients at baseline were compared to those measured in the same patients after 8 weeks of therapy. The acute phase reactants C-reactive protein (CRP) and serum amyloid A protein (SAA) decreased from baseline to week 8 in all but one subject (Figure 1). Serum albumin increased between baseline and week 8 in all but one subject. Other known important acute phase reactants including haptoglobin, alpha-1 antitrypsin (AAT) and serum amyloid A protein declined from baseline to week 8 consistent with a reduction in the disease burden.

Correlations with Severity of Disease

Microbiological and radiographic parameters are used to assess the severity of TB disease. At baseline, total cavity volume and time-to-detection in MGIT culture are markers of severity of disease and bacillary burden in the sputum, respectively. Among the data available for the patients involved in our study, CXR class (as defined by presence cavitation and size on baseline CXR, class 1 = no cavitation; class 2 = cavitation present, <4 cm in size; class 3 = cavitation present, >4 cm in size) showed the strongest association with other parameters such as body mass index (BMI, Figure 2A) and time-to-detection in MGIT culture (TTD, Figure 2B), and as expected, both were lower in the 13 patients with large and/or bilateral cavities (CXR class 3) compared to the 17 patients without cavitory disease (CXR class 1), but there was substantial overlap between groups. Plasminogen (Figure 2C), which was lower in CXR class 3 compared to class 1 and thrombospondin-2 (TSP-2), which was higher in CXR class 3 compared to class 1 (Figure 2D) best discriminate CXR class 1 from class 3 patients, though these effects had an 18% false discovery rate, so on average we expect roughly 1 in 6 such effects to be “false” discoveries.

The top markers at baseline distinguishing the thirteen patients with more severe disease (score >0.60) and the thirteen patients with less severe disease (score <0.40) were CRP, SAA, and NPS-PLA2 with roughly two-fold increased levels of the median.

Regression analysis was used to identify proteins that changed with increasing disease severity as measured by our custom, composite score. Using baseline (log) RFU as the response in a linear model and a 5% false discovery rate, Heparin cofactor 2, platelet factor-4 (PF-4), G-protein coupled receptor associated sorting protein-2 (GASP-2), and α2-antiplasmin had baseline concentrations that were correlated with our disease severity score (Figure 3A–D). Low levels of heparin cofactor 2 and GASP2 were both associated with more severe disease. Interestingly, α2-antiplasmin levels at 8 weeks also decreased with increasing severity scores (Figure 3E). In contrast, fibrinogen levels measured at 8 weeks were higher in patients with severe disease (Figure 3F). Regression analysis using the (log 2) ratio of week 8 to baseline concentration and a 5% false discovery rate uncovered additional proteins whose rate of change was associated with disease severity. The top markers were DKK-1, adiponectin and serum amyloid P component (SAP) (Figure 3G–I). DKK-1 levels decreased from baseline to 8 weeks in patients with mild disease, but remained high or even increased in patients with more severe disease. Adiponectin increased in the majority of patients with mild disease but remained unchanged in those with the highest disease severity score (data not shown).

Paired Analysis of Serum Proteins at Baseline versus Week 8 of TB Therapy

A large number of proteins had levels that changed between baseline and 8 weeks of treatment. At a 0.01% false discovery rate (q <0.0001), 239 of the 1,030 proteins measured were differentially expressed between the two time points. Sixteen proteins shifted in the same direction from baseline to week 8 in all 39 patients (11 increased and 5 decreased from baseline), and many other proteins showed a consistent shift from baseline to week 8 in at least ¾ (30 of 39) of the patients (Table 2). The top intra-subject markers (q<10^-4) are shown in Table 2 (for the list of proteins with a 0.01% false discovery rate (q<10^-7) see Table S3).

Since the signed rank test is based on the ranks of the measurements it is difficult to appreciate the magnitude of the changes for some of these proteins, so in Figure 4 we show the top ranked proteins using the median fold-change between baseline and week 8. SAA (Serum Amyloid A Protein), NPS-PLA2 (Phospholipase A2), and CRP (C-reactive Protein) showed median within-subject decreases of 6.8-fold, 5.9-fold, and 4.7-fold,

### Table 1. TB patient characteristics.

| Patient characteristics | Value (range) |
|-------------------------|---------------|
| # patients              | 39            |
| Rifampin treated (%)    | 14 (36)       |
| Age years, median       | 28.5 (19–53)  |
| Male (%)                | 28 (72)       |
| BMI median, kg/m²       | 19 (15.2–26.7)|
| Smoker (%)              | 20            |
| Alcohol use (%)         | 2             |

DOI:10.1371/journal.pone.0061002.t001
respectively, from baseline to week 8. Sixteen additional proteins dropped at least 1.5-fold (median fold change), and a few markers increased between baseline and week 8, including TSP4, antithrombin III, mannose receptor 2 (MRC-2), fetuin-like protein (FETUB) and plasma serine protease inhibitor (PCI). We next explored the paired data using the database for annotation,
visualization and integrated discovery (DAVID). Clusters based on functional annotation with an enrichment score exceeding 1.3 (corresponding to a Bonferroni corrected p-value of 0.05) were considered significant. Pathways involved in response to wounding, inflammatory response, defense response and coagulation were highly enriched. A full list of annotated clusters can be found in Figure S2.

Unpaired Analysis

For prognostic applications we would hope to predict treatment response using only a single sample and with this in mind we performed an unpaired analysis to identify proteins with baseline measurement distributions that differed from the week 8 distributions. At a 0.1% false discovery rate (q < 0.001) the KS test identified 116 of 1,030 proteins as differentially expressed between baseline and week 8. KS distances for all proteins are shown in Figure 5. The top 60 markers (q < 10^-2) are listed in Table 3 and all 116 markers (q < 0.001) are listed in Table S4. A total of 55/116 features were up-regulated and 61/116 were down-regulated over time. The most significant changes were noted for TSP4, fibroblast activation protein α (SEPR), MRC-2, antithrombin III, PCI, LPS-binding protein (LBP), α2-HS-glycoprotein, and phospholipase A2 (NPS-PLA2). The empirical cumulative distribution functions for the baseline and week-8 distributions of these markers are shown in Figure S2.

**Figure 3. Correlation of serum protein markers with TB disease severity.** Top markers that showed the largest differential expression in mild disease (n = 13) compared to severe disease (n = 13), based on medians at baseline. Log10 RFU was used as the response in a linear model and a 5% false discovery rate. A–D: Markers of disease severity identified via linear regression analysis of the protein concentration correlated with disease severity at baseline. E–F: Levels of α2-antiplasmin and fibrinogen (respectively) relative to disease severity score at 8 weeks. G–I: Markers of disease severity based on a regression analysis of the expression shift from baseline to week 8.

doi:10.1371/journal.pone.0061002.g003
Table 2. Differential protein expression between baseline and week 8 in paired samples from \( n = 39 \) patients treated for pulmonary TB.

| Rank | Target | Swiss Prot* | Intrasubject Shift (baseline to week 8) | p-value | q-value |
|------|--------|-------------|----------------------------------------|---------|---------|
| 1    | TIMP-2 | P16035      | 39                                    | 5.3e-08 | 5.48e-07 |
| 2    | GFRα-2 | O00451      | 39                                    | 5.3e-08 | 5.48e-07 |
| 3    | MRC2   | Q9UBG0      | 39                                    | 5.3e-08 | 5.48e-07 |
| 4    | Haptoglobin, Mixed Type | P00738 | 39 | 5.3e-08 | 5.48e-07 |
| 5    | LBP    | P18428      | 39                                    | 5.3e-08 | 5.48e-07 |
| 6    | amyloid precursor protein | P05067 | 39 | 5.3e-08 | 5.48e-07 |
| 7    | BGH3   | Q15582      | 39                                    | 5.3e-08 | 5.48e-07 |
| 8    | TSP4   | P35443      | 39                                    | 5.3e-08 | 5.48e-07 |
| 9    | FETUB  | Q9UGM5      | 39                                    | 5.3e-08 | 5.48e-07 |
| 10   | PCI    | P05154      | 39                                    | 5.3e-08 | 5.48e-07 |
| 11   | Kallistatin | P29622 | 39 | 5.3e-08 | 5.48e-07 |
| 12   | α2-HS-Glycoprotein | P02765 | 39 | 5.3e-08 | 5.48e-07 |
| 13   | CHL1   | O00533      | 39                                    | 5.3e-08 | 5.48e-07 |
| 14   | CDON   | Q4KMG0      | 39                                    | 5.3e-08 | 5.48e-07 |
| 15   | D-dimer | P02671, P02675, P02679 | 39 | 5.3e-08 | 5.48e-07 |
| 16   | MMP-1  | P03956      | 39                                    | 5.3e-08 | 5.48e-07 |
| 17   | contactin-1 | Q12860 | 38 | 5.7e-08 | 5.48e-07 |
| 18   | CD109  | Q6YHK3      | 38                                    | 5.7e-08 | 5.48e-07 |
| 19   | IGFBP-7 | Q16270 | 38 | 5.7e-08 | 5.48e-07 |
| 20   | Sphingosine kinase 1 | Q9NYA1 | 38 | 5.7e-08 | 5.48e-07 |
| 21   | CRP    | P02741      | 38                                    | 5.7e-08 | 5.48e-07 |
| 22   | SEPR   | Q12884      | 38                                    | 5.7e-08 | 5.48e-07 |
| 23   | TIMP-3 | P35625      | 38                                    | 6.1e-08 | 5.48e-07 |
| 24   | Lipocalin 2 | P80188 | 38 | 6.1e-08 | 5.48e-07 |
| 25   | NAP-2  | P02775      | 38                                    | 6.1e-08 | 5.48e-07 |
| 26   | Nectin-like protein 2 | Q9BY67 | 38 | 6.1e-08 | 5.48e-07 |
| 27   | Proteinase-3 | P24158 | 38 | 6.1e-08 | 5.48e-07 |
| 28   | PDGF-BB | P01127 | 38 | 6.1e-08 | 5.48e-07 |
| 29   | MMP-2  | P08253      | 38                                    | 6.1e-08 | 5.48e-07 |
| 30   | TIMP-1 | P01033      | 37                                    | 6.6e-08 | 5.48e-07 |
| 31   | ROR1   | Q01973      | 37                                    | 6.6e-08 | 5.48e-07 |
| 32   | IGFBP-6 | P24592 | 37 | 6.6e-08 | 5.48e-07 |
| 33   | PAI-1  | P05121      | 38                                    | 6.6e-08 | 5.48e-07 |
| 34   | Protein C | P04070 | 37 | 6.6e-08 | 5.48e-07 |
| 35   | C9     | P02748      | 38                                    | 6.6e-08 | 5.48e-07 |
| 36   | GDF-9  | O60383      | 37                                    | 6.6e-08 | 5.48e-07 |
| 37   | Carbonic anhydrase 6 | P23280 | 37 | 6.6e-08 | 5.48e-07 |
| 38   | RBP    | P02753      | 37                                    | 6.6e-08 | 5.48e-07 |
| 39   | Albumin | P02768 | 38 | 6.6e-08 | 5.48e-07 |
| 40   | Fibronectin | P02751 | 37 | 6.6e-08 | 5.48e-07 |
| 41   | Antithrombin III | P01008 | 38 | 7.2e-08 | 5.48e-07 |
| 42   | a1-Antitrypsin | P01009 | 37 | 7.2e-08 | 5.48e-07 |
| 43   | HRG    | P04196      | 38                                    | 7.2e-08 | 5.48e-07 |
| 44   | Angiopoietin-1 | Q15389 | 38 | 7.8e-08 | 5.48e-07 |
| 45   | AT513  | Q76LX8      | 37                                    | 7.8e-08 | 5.48e-07 |
| 46   | Coagulation Factor VII | P08709 | 37 | 7.8e-08 | 5.48e-07 |
| 47   | Afamin | P43652      | 38                                    | 7.8e-08 | 5.48e-07 |
protein measurements (along with an indication of the KS distance between the distributions) for the top eight markers are shown in Figure 6, and the plots for 59 additional proteins are available in Figure S3. A scatter plot using the top two markers that were differentially expressed between baseline and 8 week samples can be seen in Figure 7. Using measurements of one or more of these proteins it is possible classify each sample within this data set as belonging to either the baseline group (TB) or the week 8 group (treated TB) with sensitivity and specificity exceeding 90% (data not shown).

**Table 2.** Cont.

| Rank | Target                      | Swiss Prot*       | Intrasubject Shift (baseline to week 8) | p-value | q-value |
|------|-----------------------------|-------------------|----------------------------------------|---------|---------|
| 48   | TrkB                        | Q16620            | Up (n): 37                             | 7.8e-08 | 5.48e-07|
| 49   | GOT1                        | P17174            | Down (n): 38                           | 7.8e-08 | 5.48e-07|
| 50   | Azurocidin                  | P20160            |                                        | 8.4e-08 | 5.80e-07|
| 51   | NCAM-L1                     | P32004            |                                        | 9.1e-08 | 6.03e-07|
| 52   | PLXCl                       | O60486            |                                        | 9.1e-08 | 6.03e-07|
| 53   | I-TAC                       | O14625            |                                        | 1.1e-07 | 6.41e-07|
| 54   | CYTF                        | O76096            |                                        | 1.1e-07 | 6.41e-07|
| 55   | BPI                         | P17213            |                                        | 1.1e-07 | 6.41e-07|
| 56   | HNRPEQ                      | O60506            |                                        | 1.1e-07 | 6.41e-07|
| 57   | PHI                         | P06744            |                                        | 1.1e-07 | 6.41e-07|
| 58   | Cathepsin G                 | P08311            |                                        | 1.1e-07 | 6.47e-07|
| 59   | Osteoblast-specific transcription factor 2 | Q13950 | Up (n): 37 | 1.1e-07 | 6.47e-07|
| 60   | SAA                         | P02735            |                                        | 1.1e-07 | 6.47e-07|
| 61   | TXD12                       | O95881            |                                        | 1.1e-07 | 6.47e-07|
| 62   | gp130, soluble              | P40189            |                                        | 1.2e-07 | 6.87e-07|
| 63   | ITI heavy chain H4           | Q14624            |                                        | 1.3e-07 | 7.30e-07|
| 64   | CDK8/cyclin C               | P49336, P24863    |                                        | 1.4e-07 | 7.63e-07|
| 65   | VEGF121                     | P15692            |                                        | 1.4e-07 | 7.63e-07|
| 66   | LRIG3                       | Q6UXM1            |                                        | 1.5e-07 | 7.98e-07|
| 67   | MAPK14                      | Q16539            |                                        | 1.5e-07 | 7.98e-07|
| 68   | PGRP-5                      | O75594            |                                        | 1.7e-07 | 8.24e-07|
| 69   | RGM-C                       | Q6ZVN8            |                                        | 1.7e-07 | 8.24e-07|
| 70   | Fibrinogen g-chain dimer    | P02679            |                                        | 1.7e-07 | 8.24e-07|
| 71   | MMP-9                       | P14780            |                                        | 1.8e-07 | 8.52e-07|
| 72   | Thyroxine-Binding Globulin  | P05543            |                                        | 1.8e-07 | 8.52e-07|
| 73   | Cadherin-5                  | P33151            |                                        | 1.8e-07 | 8.52e-07|
| 74   | NPS-PLA2                    | P14555            |                                        | 1.9e-07 | 9.07e-07|
| 75   | NAP-2                       | P02775            |                                        | 2.1e-07 | 9.51e-07|
| 76   | FN1.3                       | P02751            |                                        | 2.1e-07 | 9.51e-07|
| 77   | Protease nexin I            | P07093            |                                        | 2.3e-07 | 9.99e-07|
| 78   | Plasminogen                 | P00747            |                                        | 2.3e-07 | 9.99e-07|

At a false discovery rate of 10^{-2}, 78 of 1,030 proteins were identified as differentially expressed using the Wilcoxon Signed Rank test (for all 239 proteins with q < 10^{-4} see Table S3). The intra-subject shifts indicate the number of patients showing up or down-regulation. Also shown are the raw p-value and resulting FDR corrected “q-value”.

*Swiss Prot is a large protein sequence database widely used for protein resources.

doi:10.1371/journal.pone.0061002.t002

**Discussion**

In this study, we conducted unbiased targeted proteomic analysis employing modified DNA aptamers to identify and quantify protein markers that were associated with active TB and that changed in response to four-drug treatment. To date, we have conducted several other blood-based clinical biomarker studies of human diseases, including lung cancer [3], West Nile Virus infection (unpublished) and chronic kidney disease [2]. These studies have identified novel disease biomarkers as well as confirmed associations of previously reported biomarkers. Recent biomarker discovery programs aimed at identifying novel TB biomarkers with demonstrable utility have been successful [17–19]. Among the analytical tools for TB biomarker discovery,
transcriptional microarray [17,20,21], 2D gel analysis [22], and mass spectroscopy [18,23] have been used but none, to our knowledge, has undertaken such a large-scale analysis for the targeted detection of protein levels in the serum of patients with TB disease.

Increasing serum albumin levels and declining levels of acute phase reactant proteins over time gives confidence in our findings as it is consistent with the anticipated improvement of TB patients in response to combination drug therapy. We observed a lack of change in classically described soluble cytokines (e.g. interferon-γ,
Table 3. Unpaired analysis of proteins showing differential expression between baseline and week 8 in *n* = 39 TB patients.

| Rank | Target                          | Swiss Prot* | KS-distance (Signed) | q-value | p-value |
|------|---------------------------------|-------------|----------------------|---------|---------|
| 1)   | TSP4                            | P35443      | 0.821                | 1.37e-12| 1.06e-09|
| 2)   | SEPR                            | Q12884      | 0.769                | 4.08e-11| 1.05e-08|
| 3)   | MRC2                            | Q9UBG0      | 0.769                | 4.08e-11| 1.05e-08|
| 4)   | Antithrombin III                | P01008      | 0.744                | 2.05e-10| 3.15e-08|
| 5)   | PCI                             | P05154      | 0.744                | 2.05e-10| 3.15e-08|
| 6)   | LBP                             | P18428      | −0.718               | 9.73e-10| 6.25e-08|
| 7)   | α2-HS-Glycoprotein              | P02765      | 0.718                | 9.73e-10| 6.25e-08|
| 8)   | NPS-PLA2                        | P14555      | −0.718               | 9.73e-10| 6.25e-08|
| 9)   | Haptoglobin, Mixed Type         | P00738      | −0.718               | 9.73e-10| 6.25e-08|
| 10)  | Kallistatin                     | P29622      | 0.718                | 9.73e-10| 6.25e-08|
| 11)  | MMP-2                           | P08253      | 0.718                | 9.73e-10| 6.25e-08|
| 12)  | NCAM-L1                         | P32004      | 0.718                | 9.73e-10| 6.25e-08|
| 13)  | CDON                            | Q4KMG0      | 0.692                | 4.38e-09| 2.60e-07|
| 14)  | Fibronectin                     | P02751      | 0.667                | 1.87e-08| 1.03e-06|
| 15)  | Cathepsin G                     | P08311      | −0.641               | 7.53e-08| 2.23e-06|
| 16)  | gp130, soluble                  | P40189      | 0.641                | 7.53e-08| 2.23e-06|
| 17)  | Nectin-like protein 2           | Q9BY67      | 0.641                | 7.53e-08| 2.23e-06|
| 18)  | LEAP-1                          | P81172      | −0.641               | 7.53e-08| 2.23e-06|
| 19)  | CRP                             | P02741      | −0.641               | 7.53e-08| 2.23e-06|
| 20)  | Fibrinogen g-chain dimer        | P02679      | −0.641               | 7.53e-08| 2.23e-06|
| 21)  | TIMP-2                          | P16035      | 0.641                | 7.53e-08| 2.23e-06|
| 22)  | IL-19                           | Q9UHD0      | 0.641                | 7.53e-08| 2.23e-06|
| 23)  | CDK8/cyclin C                   | P49336, P24863| −0.641   | 7.53e-08| 2.23e-06|
| 24)  | CHL1                            | O00533      | 0.641                | 7.53e-08| 2.23e-06|
| 25)  | D-dimer                         | P02671, P02675, P02679| −0.641 | 7.53e-08| 2.23e-06|
| 26)  | CATZ                            | Q9UBR2      | 0.641                | 7.53e-08| 2.23e-06|
| 27)  | TrkC                            | Q16288      | 0.615                | 2.88e-07| 7.15e-06|
| 28)  | Fibrinogen                      | P02671, P02675, P02679| −0.615 | 2.88e-07| 7.15e-06|
| 29)  | Angiopoietin-1                  | Q15389      | −0.615               | 2.88e-07| 7.15e-06|
| 30)  | Lipocalin 2                     | P80188      | −0.615               | 2.88e-07| 7.15e-06|
| 31)  | C9                              | P02748      | −0.615               | 2.88e-07| 7.15e-06|
| 32)  | MMP-9                           | P14780      | −0.590               | 1.04e-06| 1.82e-05|
| 33)  | I-TAC                           | O14625      | −0.590               | 1.04e-06| 1.82e-05|
| 34)  | BMP-1                           | P13497      | 0.590                | 1.04e-06| 1.82e-05|
| 35)  | BMPER                           | Q88809      | 0.590                | 1.04e-06| 1.82e-05|
| 36)  | Plasminogen                     | P00747      | 0.590                | 1.04e-06| 1.82e-05|
| 37)  | PHI                             | P06744      | −0.590               | 1.04e-06| 1.82e-05|
| 38)  | Trk8                            | Q16620      | 0.590                | 1.04e-06| 1.82e-05|
| 39)  | Coagulation Factor IX           | P00740      | −0.590               | 1.04e-06| 1.82e-05|
| 40)  | GOT1                            | P17174      | −0.590               | 1.04e-06| 1.82e-05|
| 41)  | RBP                             | P02753      | 0.590                | 1.04e-06| 1.82e-05|
| 42)  | Albumin                         | P02768      | 0.590                | 1.04e-06| 1.82e-05|
| 43)  | Sphingosine kinase 1            | Q9NYA1      | −0.590               | 1.04e-06| 1.82e-05|
| 44)  | Afinmin                         | P43652      | 0.590                | 1.04e-06| 1.82e-05|
| 45)  | TIMP-1                          | P01033      | −0.564               | 3.56e-06| 4.58e-05|
| 46)  | GFRA-2                          | O00451      | 0.564                | 3.56e-06| 4.58e-05|
| 47)  | Azurocidin                      | P20160      | −0.564               | 3.56e-06| 4.58e-05|
| 48)  | Lactoferrin                     | P02788      | −0.564               | 3.56e-06| 4.58e-05|
| 49)  | amyloid precursor protein        | P05067      | −0.564               | 3.56e-06| 4.58e-05|
Biomarkers of Inflammation and Anti-microbial Defense

We identified differentially expressed proteins involved in innate and adaptive immunity to which antimicrobial function has been attributed, including but not limited to; complement cascade components, CRP [27], α1 antitrypsin (AAT) [28,29], hepcidin (LEAP) [30], bactericidal permeability increasing protein (BPI) [31], lipopolysaccharide binding protein (LBP) [32] and phospholipase A2 (NPS-PLA2) [33] which all decreased over time in the majority of patients. Components of the MTB bacillus are known to induce the immune system [36] was among the top 3 markers that were significantly changes known to occur with TB therapy. Among the diverse pathways we identified, the most predominant were those representing the core biological themes of antimicrobial defenses and tissue remodeling/healing functions.

A total of 60 proteins were differentially expressed using the KS test and 0.01% false discovery rate (q < 10^{-4}; for all 116 proteins with q < 10^{-3} see Table S4). The shift in expression is shown as the signed KS-distance, with a positive KS value indicating up-regulation of the protein after 8 weeks of TB therapy. Also shown are the raw p-value and resulting FDR corrected “q-value”.

| Rank | Target | Swiss Prot* | KS-distance (Signed) | p-value | q-value |
|------|--------|-------------|----------------------|---------|---------|
| 50   | RET    | P07949      | 0.564                | 3.56e-06 | 4.58e-05 |
| 51   | LIRG3  | Q6UXM1      | 0.564                | 3.56e-06 | 4.58e-05 |
| 52   | CD30 Ligand | P32971 | 0.564                | 3.56e-06 | 4.58e-05 |
| 53   | Osteoblast-specific transcription factor 2 | Q13950 | 0.564                | 3.56e-06 | 4.58e-05 |
| 54   | Proteinase-3 | P24158 | −0.564               | 3.56e-06 | 4.58e-05 |
| 55   | MASP3  | P48740      | 0.564                | 3.56e-06 | 4.58e-05 |
| 56   | HNRPQ  | O60506      | −0.564               | 3.56e-06 | 4.58e-05 |
| 57   | SAA    | P02735      | −0.564               | 3.56e-06 | 4.58e-05 |
| 58   | PLX1C1 | O60486      | 0.564                | 3.56e-06 | 4.58e-05 |
| 59   | Coagulation Factor IX | P00740 | −0.564               | 3.56e-06 | 4.58e-05 |
| 60   | CAPG   | P40121      | −0.564               | 3.56e-06 | 4.58e-05 |

*tSwiss Prot is a large protein sequence database widely used for protein resources.

doi:10.1371/journal.pone.0061002.t003

Biomarkers of Tissue Remodeling

In this work, we discovered many proteins involved in tissue healing including proteases and anti-proteases, fibrotic process proteins, remodeling of collagen and extracellular matrix (ECM) as well as members of the coagulation cascade. Plasminogen, a marker found in all analyses has been reported to be co-opted by MTB [37] and other respiratory pathogens [38] in order to evade immune responses. Once activated, plasminogen is converted to plasmin, a serine protease that can degrade fibrin and activate complement [39]. Plasmin has also been reported to increase the activity of many proteins including matrix metalloproteinases (MMP) and TGF-β which can alter host pathology and allow the tubercle bacillus to disseminate more readily [40–42]. Thrombospondin-4 (TSP4) prominently appears in both the paired and unpaired analysis. The thrombospondins are a family of extracellular matrix glycoproteins that mediate cell-to-cell and cell-to-tissue interactions. They have been reported to be involved in lung adhesion, fibrosis, neovascularization and cardiac tissue remodeling [43–47], but to our knowledge they have not been associated with active TB. Fibroblast activation protein (SEP4) is also involved in collagen and extracellular matrix degradation. Additional MMPs and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs) are both classes of enzymes involved in fibrosis and the proper formation of granulomatous inflammation [42,48–53], tissue remodeling and turnover of extracellular matrix material in normal and pathological conditions [54–57]. The differential expression of these proteins may relate to underlying cavitary disease, resolution of liquefaction, local hypoxia and ultimate healing with fibrosis [57].

Biomarkers of Angiogenesis and Coagulation

Angiogenesis is a complex biological phenomenon controlled by both positive and negative signals. The finding of 3 forms of vascular endothelial growth factor (VEGF) or its receptor among the top markers changing over time supports an intriguing role for angiogenesis and vascular remodeling and has recently been shown by others to be associated with TB [58–60]. We found significant changes in levels of proteins members (e.g. antithrombin III) of the coagulation cascades highlighting the importance of such cascades in the course of TB. There is a pro-coagulant state
Figure 6. Empirical cumulative distribution functions showing Log RFU for the eight proteins with largest KS distances between baseline and week 8.
doi:10.1371/journal.pone.0061002.g006
in TB [61–63] and others have shown that hematologic/coagulation factors can be biomarkers of TB infection [64]. Indeed careful study of lung histopathology of human and experimental MTB infection reveals areas of vasculitis [34] and microthrombi within vessels contributing to lesion formation [65].

Biomarkers Associated with Disease Severity

When considering markers associated with the severity of disease a few proteins are worthy of specific comment. The levels of thrombospondin-2 (TSP-2), a protein regulating a variety of cell-matrix interactions [66] was found to be higher in those with more cavitary manifestations of disease. Three additional markers stood out in a logistic regression analysis of disease severity: DKK-1, serum amyloid P and adiponectin. DKK-1 an inhibitor of wnt signaling has also been shown to alter fibrosis [67] and expression is up-regulated in a Chlamydia infection model [68]. Serum amyloid P is a member (as is CRP) of the pentraxin family of proteins involved in pattern recognition and complement activation [59] and levels have been shown to correlate with disease severity and rapidity of burn wound healing [69]. Adiponectin is associated with metabolic syndrome and insulin resistance [70] and is known to be increased with decreased body fat so the finding of low levels with severe disease would argue against the association being attributed exclusively to low BMI in our patients. Adiponectin may be important in the lung, as receptors for this adipokine have been shown in the lung and low levels of adiponectin are associated with development of other serious pulmonary diseases (e.g. asthma) [71].

Many of the proteins identified throughout this work do not necessarily follow previous reports of mRNA transcript changes in TB [21] and suggest that each analytical method may be describing different cellular/host processes or reflect intrinsic differences between these two types of global analysis [72]. While drug treatment effects certainly could manifest with changes in serum proteins, we do not believe that all of such a large number of markers identified and the substantial magnitudes of the differential expression we observed are due to drug treatment alone but this remains to be studied. Proteins like cytochrome P450 enzymes (e.g. Cyp3A4) [73] and other drug metabolizing enzymes such as the superoxide dismutases (Sod1 and Sod2) and peroxiredoxins (Prdx1 and Prdx2) did not show any differential expression. In addition, we did not observe increases in typical markers of hepatotoxicity (aspartate aminotransferase) [74,75]. Since rifampin is a broad spectrum antimicrobial agent we cannot conclusively rule out effects on gut microbial translocation, but it is useful to note that the samples used in this study were taken from a subset of the parent trial patients and were chosen to be free of co-morbidities like HIV infection, hepatitis C, diabetes, significant alcohol/drug use and cirrhosis; conditions which have been associated with increased microbial translocation. Even markers such as LBP and BPI have been associated with non-gram-negative infections and even with mycobacterial components [31,32] lending support to our conclusions that the observed changes are unlikely to be the result of non-specific treatment effects on the microbiome but rather are due to treatment of TB disease itself. However, to answer this completely will require more rigorously designed clinical trials.

We recognize the limitations of this work. Small sample sizes, the omnipresence of pre-analytical variability, lack of suitable healthy-state and disease controls and studying a non-target organ (serum and not lung) are but a few of the challenges. Despite these limitations, the data contribute to further understanding of the complexity of changes accompanying TB disease.

We have presented overall false discovery rates for each list of proteins and listed individual q-values in each comparison. The latter are analogous to p-values in that they convey the significance of the result. For example, in a list of proteins q-values as large as 0.001 we expect on average of 1/1,000 proteins to eventually turn out to be “false discoveries”. Also, many of these markers share common pathways, regulators, or ontology, and their biological functions make sense in light of TB infection and disease (such as antimicrobial and tissue healing pathways). Finding such consistent themes within markers is intriguing and may further reduce the chance that these proteins are false discoveries.

Our current study has identified novel markers not previously reported to be associated with tuberculosis. Some of the biomarkers identified here are novel to the field of TB and will provide a new perspective on TB biology. With both familiar and new elements yielding intriguing findings, our study has contributed to the understanding of many aspects of TB infection as well as the complex adaptive systems involved in treatment of TB. We present this preliminary characterization of TB disease markers as an example of what can be done with such data, however, our findings still require future testing in properly designed validation studies using independent sample test sets with proper disease controls. Our study primarily assessed serum biomarkers of severity of disease and response to effective drug therapy, but we believe that our findings provide a platform for future investigation into the use of aptamer technology for diagnostic, drug efficacy and toxicity monitoring applications in TB.

Methods

Ethics Statement

TBTC: Study 29 was approved by the institutional review boards of all participating institutions and the Center for Disease Control and Prevention (CDC), and registered with clinicaltrials.gov (Trial identifier: NCT00694629). Additionally, IRB approval was obtained from the Committee on Human Research of the University of California, San Francisco for the pilot evaluation of
serum-based biomarkers for predicting response to TB treatment (H45279-34102-02A).

Study Design and Data Analysis

TBTC Study 29 was a prospective, multicenter, open-label Phase 2B clinical trial comparing the antimicrobial activity and safety of standard TB therapy comprised of rifampin, isoniazid, pyrazinamide and ethambutol to that of an experimental regimen of rifapentine (10 mg/kg/dose), isoniazid, pyrazinamide and ethambutol in patients with drug-susceptible, smear-positive pulmonary TB. All patients signed a written informed consent. TBTC Study 29 methods and primary study results are published [4]. Briefly, all study participants were adults (age ≥ 18 years) and had culture confirmed drug-susceptible TB diagnosed by sputum culture, agreed to HIV testing, had reasonably normal renal, hepatic and hematologic function, had no major co-morbidities. All received directly observed therapy (DOT) five of seven days a week, with up to 5 days of pre-enrollment treatment permitted before entry in the parent trial. As part of the biomarker sub-study of TBTC Study 29, serum was collected, processed and stored at baseline (time of enrollment into Study 29), and after 8 weeks (40 doses) of intensive phase therapy. For this project, additional end of treatment information including total duration of treatment and end of treatment cure status, was abstracted from patient charts by GM in Kampala, Uganda. For this pilot project, 39 HIV-uninfected study participants from the TBTC site in Kampala, Uganda without significant co-morbidities reported at enrollment were randomly selected by PN from participants enrolled from December, 2008 to July, 2009. Baseline and end of intensive phase treatment serum samples were analyzed. The SOMAscan assay was performed following standard protocols [1] and was carried out in full before receiving any clinical or demographic data. After all analyses were complete, data were submitted to the CDC after which clinical, radiographic and microbiologic data were shared with SomaLogic. After analysis of serum and receipt of the clinical data, a custom disease severity score was calculated based on chest radiograph (CXR) extent and cavitary disease (absent, diameter of all cavities summed less than or greater than 4 cm [5], sputum smear grade [6], days to detection of a positive culture in liquid media inoculation and body mass index [weight in kg/(height in m)^2]. A clinical spectrum of severity was determined to see if further refinement of disease severity could elucidate markers associated with more severe disease. Given the clinical importance of BMI [7] and bilateral cavitation [8] these factors were weighted by a factor of 2. Details regarding the calculation of the custom disease severity score (normalization, weighting, and calibration) can be found in Table S1, and the calculated custom disease severity scores are shown in Table S2 and Figure S1.

SomaLogic Proteomic Methods

SomaLogic Inc., (Boulder, CO) performed all proteomic assessments and was blinded to the clinical characteristics of participating patients from whom sera was obtained for this study. Samples were analyzed in a single assay run and data validation was performed using internal assay controls without a priori knowledge of time point, clinical or microbiological details. SOMAmers were selected in vitro by the SELEX process (Systematic Evolution of Ligands by Exponential Enrichment) which consists of multiple rounds of selection, partitioning, and amplification [9,10]. Success of SELEX and affinity of these binding reagents have greatly improved since using modified nucleotides to expand the chemistry of DNA for in vitro selection [11]. Version 2 SOMAscan assay, containing SOMAmers with sub-nanomolar K_d’s, was used to test serum at three different concentrations (5%, 0.3%, 0.01%) to obtain accurate measurements within the dynamic range of the assay for low-, medium-, and high-abundant proteins, respectively. The integrity of serum samples provided for testing was monitored for known sample handling artifacts [3]. The SOMAmer-based proteomic assay consists of equilibrium binding of fluorophore-tagged SOMAmers and proteins in plasma or serum in solution and automated partitioning steps to capture only the SOMAmers that are in complexes with their cognate proteins [2]. The assay transforms the measurement of proteins into the measurement of the corresponding SOMAmers (DNA), via hybridization to an antisense probe array using a hybridization gasket slide with eight microarrays per slide (Agilent Technologies, Santa Clara, CA, USA). The liquid handling steps of the assay (protein binding) are performed by a Biomek robot, and the fluorescent signal generated in the hybridization step is captured. For this study, protein concentrations were reported in relative fluorescence units (RFU).

Data Analysis and Statistical Method

Statistical analysis was performed using both Matlab™ and the R environment for statistical computing (http://www.r-project.org/). The Wilcoxon signed rank test was used for paired (within-subject) comparisons. To identify proteins differentially expressed between the baseline and week 8 time points. The Kolmogorov-Smirnoff (KS) test was used for unpaired comparisons between the baseline and week 8 populations. The KS statistic is an unsigned quantity, though to aid interpretation, we report a “signed” value using the sign to convey the directionality in the differential expression (that is, positive or negative KS distances for increased or decreased protein levels in a given comparison of interest). Multiple comparison corrections were performed using the false discovery rate (FDR) methodology [12] and we report both p-values and the associated FDR corrected “q-values” computed with the R package q-value [13]. We chose a nominal 0.01% false discovery rate to achieve a manageable number of proteins to consider while maintaining an acceptable expected number of false discoveries. The database for annotation, visualization and integrated discovery (DAVID) analysis was used for functional clustering and annotation (http://david.abcc.ncifcrf.gov/) [14–16].

Supporting Information

Figure S1 Disease severity custom score for 39 participants. The custom score was calculated from eight parameters as shown in Table S1 and was based on the individual values shown in Table S2.

(TIF)

Figure S2 DAVID analysis of paired sample data set. Annotation Clusters, enrichment scores, and Bonferroni-corrected p-values are provided in spreadsheet format (XLSX).

(XLSX)

Figure S3 Empirical cumulative distribution functions for the top 59 proteins from an unpaired analysis. Proteins were measured at baseline (blue) and week 8 (red) in samples from n = 39 TB patients. The legend shows Bonferroni corrected p-value ranges associated with each color of the plot area.

(TIF)

Table S1 Disease severity score calculation. Eight parameters were combined into a custom disease severity score. CXRCLASS (Chest X-ray cavitation classification), 1–3, the higher the worse, absent (1), < 4 cm (2), > 4 cm (3); CXREXTNT
(Chest X-ray extent of disease). A to C (converted to 1–3), limited (A), moderate (B), extensive (C); dd_base (days to detection at baseline), the lower the worse (quicker detection if microbial burden is high); smearb (bacillus count in sputum sample via microscopy), 1–4, the higher the worse; bmi (body mass index at enrollment in kg/m^2), the lower the worse (weight loss is a known effect of TB disease); anycav, 0 or 1 (1 = any cavitation reported at enrollment); bilatcav, 0 or 1 (1 = bilateral cavities reported at enrollment); bilatab, 0 or 1 (1 = bilateral abnormalities - adenopathy, pleural disease, infiltrates or cavities).

Table S2 Disease severity parameters and custom score calculation for 39 participants. The parameters were normalized and weighed as shown in Table S1, and combined into a total score, then scaled to values from 0-1 to result in the custom score = (Total score +10) / 16. A plot showing all participants and their custom score for disease severity is shown in Figure S1.

Table S3 Differential protein expression between baseline and week 8 in paired samples from n=39 patients treated for pulmonary TB. At a 0.01% false discovery rate (q <10^-4) a total of 239 proteins were identified as differentially expressed using the Wilcoxon Sign Rank test. The intra-subject shifts are shown as the number of patients showing up- or down-regulation. Also shown are p-values for individual comparison and false discovery rate corrected q-values.

Table S4 Unpaired analysis of proteins showing differential expression between baseline and week 8 in n=39 TB patients. At a 0.1% false discovery rate (q <0.001), a total of 116 proteins were differentially expressed. The shift in expression is shown as a signed KS-distance, with a positive KS distance indicating up-regulation of the protein after 8 weeks of TB therapy.

Acknowledgments

We thank our SomaLogic colleagues who contributed to this study (in particular S. Williams, R. Ostroff, T. Foreman and M. Menzenbaugh), and the many staff scientists who performed the SOMAscan assay and developed the tools for this technology. We also thank Erin Bliven-Sizemore of the United States Centers for Disease Control and Prevention for data coordination and we are especially grateful to all of the TB patients enrolled in Study S29 and the staff in Uganda.

Author Contributions

Performed sample procurement and provided the clinical data: LJ PN MW JJM. Initiated and coordinated TB efforts at SomaLogic: MADG. Leading the Infectious Disease/Microbiology programs at SomaLogic: UO, Chief Science Officer and oversaw the project: NJ. Conceived and designed the experiments: PN UO MADG. Performed the experiments: DS UO MADG. Analyzed the data: UO MADG DS. Contributed reagents/materials/analysis tools: UO NJ DS PN MW. Wrote the paper: MADG PN UO.

References

1. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehą M, et al. (2010) Unlocking biomarker discovery: large scale application of aptamer protein technology for early detection of lung cancer. PloS one 5: e15003.
2. Gold L, Ayers D, Bertino J, Bock C, Bock A, et al. (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PloS one 5: e15004.
3. Ostroff R, Foreman T, Keeney TR, Stratford S, Walker JJ, et al. (2010) The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteins array. Journal of proteomics 73: 649–666.
4. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JJ, et al. (2012) Screening of infectious diseases 20C: 1030–1040.
5. Kalka S, Wexler HM, Boeck L, Adegnika AA, Clement E, et al. (2011) Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. The journal of infectious diseases 195: 357–365.
6. Agrawal R, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, et al. (2006) Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368: 1012–1021.
7. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, et al. (2010) An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973–977.
8. Takata S, Sakurada S, Kano K, Takahashi E, Yamaota K, et al. (2011) Identification of tuberculosis-associated proteins in whole blood supernatant. BMC infectious diseases 11: 71.
9. Song QB, Hu WG, Wang P, Yao Y, Zeng HZ (2013) Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS. Acta pharmacologica Sinica 32: 1357–1362.
10. Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, et al. (2009) Biomarkers for tuberculosis disease activity, cure, and relapse. The Lancet infectious diseases 9: 162–172.
11. Nemeth J, Winkler HM, Bockel I, Adegikua AA, Clement E, et al. (2011) Specific cytokine patterns of pulmonary tuberculosis in Central Africa. Clinical immunology 138: 50–59.
12. Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, et al. (2011) Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. American journal of respiratory and critical care medicine 184: 1153–1163.
13. Tan SS, Ng PM, Ho B, Ding JL (2003) The antimicrobial properties of C-reactive protein (CRP). Journal of endotoxin research 11: 249–256.
14. Shapiro L, Port GB, Kalsot AH (2001) Alpha-l-antitrypsin inhibits human immunodeficiency virus type 1. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15: 115–122.
15. Chan ED, Kaminska AM, Gill W, Chamura K, Feldman NE, et al. (2005) Alpha-l-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scandinavian journal of infectious diseases 39: 690–696.
30. Sow FB, Ndanukumar S, Velu V, Kellar KL, Schlesinger LS, et al. (2011) Mycobacterium tuberculosis components stimulate production of the antimicrobial peptide hepcidin. Tuberculosis 91: 314–321.

31. Juffernm NF, Verbon A, van Deventer SJ, Bouman WA, van Deutekon H, et al. (1990) Serum concentrations of lipo polysaccharide activity-modulating proteins during tuberculosis. The Journal of infectious diseases 178: 1839-1842.

32. Schroder NW, Schumann RR (2005) Non-LPS targets and actions of LPS binding protein (LBP). Journal of endotoxin research 11: 237-242.

33. Qu XD, Leher R1 (1998) Secretory phospholipase A2 is the principal bactericde for staphylococci and other gram-positive bacteria in human tears. Infection and immunity 66: 2791-2797.

34. Hunter KL (2011) Pathology of post primary tuberculosis of the lung: An illustrated critical review. Tuberculosis 91: 497-509.

35. Reece ST, Loddenkemper C, Askew DJ, Zedler U, Schommer-Leitner S, et al. (2010) Serine protease activity contributes to control of Mycobacterium tuberculosis in hyperoxic lung granulomas in mice. The Journal of clinical investigation 120: 3365-3376.

36. Rajaram MV, Brooks MN, Morris JD, Torrelles JB, Azad AK, et al. (2010) Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses. Journal of immunology 185: 929-942.

37. de la Paz Santangelo M, Gest PM, Guerin ME, Coincon M, Pham H, et al. (2010) Serine protease activity correlates with mucosal leishmaniasis. Acta tropica 119: 160–164.

38. Juffermans NP, Verbon A, van Deventer SJ, Buurman WA, van Deutekom H, et al. (2011) Glycolytic and non-glycolytic functions of Mycobacterium tuberculosis fructose-1,6-bisphosphate aldolase, an essential enzyme produced by replicating and non-replicating bacilli. The Journal of biological chemistry 286: 40219-40231.

39. Sow FB, Nandakumar S, Velu V, Kellar KL, Schlesinger LS, et al. (2011) Mycobacterium tuberculosis inhibits fructose-1,6-bisphosphate aldolase, an essential enzyme produced by replicating and non-replicating bacilli. The Journal of biological chemistry 286: 40219-40231.

40. Friedland JS, Shaw TC, Price NM, Dayer JM (2002) Differential regulation of matrix metalloproteinase-1,9 and tissue inhibitors of metalloproteinase-1,2 in exudative pleural effusions. Clinical and investigative medicine Medecine clinique et experementale 32: E290-300.

41. Sato J, Schorey J, Ploplis VA, Haalboom E, Krahule L, et al. (2003) The MMP-1/9 and TIMP-1 secretion in human monocytic cells in response to Mycobacterium tuberculosis infection. Infection and immunity 71: 1905–1910.

42. Salgame P (2011) MMPs in tuberculosis: granuloma creators and tissue destroyers. The Journal of biological chemistry 286: 40219–40223.

43. Paulissen G, Rocks N, Gueders MM, Crahay C, Quesada-Calvo F, et al. (2009) MMPs in tuberculosis and the identification of potential diagnostic biomarkers. PLoS one 7: e30626.

44. Smit van Dixhoorn MG, Mulier R, Sussman G, Stad R, de Haan M, et al. (2008) Genetic expression profiling of suppressor mechanisms in tuberculosis. Molecular immunology 45: 1573-1586.

45. Basaraba RJ (2008) Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis 88: 835–847.

46. Armstrong LG, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE, et al. (2002) Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Molecular biology of the cell 13: 1893–1903.

47. Akhmetshina A, Palumbo K, Dees C, Bergmann G, Venalis P, et al. (2012) Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nature communications 3: 735.

48. Armstrong LG, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE, et al. (2002) Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Molecular biology of the cell 13: 1893–1903.

49. Almotairi H, Kamesh K, de Vries N, Meilleur N, Lammers G, et al. (2007) Mycobacterium tuberculosis uses the complement component 5b-9a to induce apoptosis in human monocytes. Journal of virology 81: 9696–9702.

50. Juncker-Jensen A, Lund L (2011) Glycolytic and non-glycolytic functions of Mycobacterium tuberculosis. The Journal of biological chemistry 286: 40219-40231.

51. Anand SP, Selvaraj P (2009) Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinase-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. Clinical immunology 133: 129–134.

52. Maretti-Mira AC, de Pinho Rodrigues KM, de Oliveira-Neto MP, Pirmez C, Craft N (2011) MMP-9 activity is induced by Lactobacillus casei infection and correlates with macrophage interleukins. Acta tropica 119: 160–164.

53. Vaivasever S, Selgasen R, Uzun H, Yurt S, Kosar F (2009) Potential role of matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinase-1,2 in exudative pleural effusions. Clinical and investigative medicine Medecine clinique et experementale 32: E290-300.

54. Taylor JF, Harte JM, Dore SA, Tebbutt JM, Izzo LS, et al. (2006) Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infection and immunity 74: 6135–6144.

55. Juncker-Jensen A, Lund L (2011) Phenotypic Overlap between MMP-13 and the Plasminogen Activation System during Wound Healing in Mice. PlosOne 6.